April 09, 2021
Article
The first step toward operationalizing the uptake of biosimilars is having a program-level discussion that not only describes what biosimilars are, but also assesses how they impact the bottom line and could get incorporated into treatment plans.
The discovery points to a novel treatment target for shrinking brain tumors that arise secondary to breast cancer, according to the study authors.
Opdivo-based combinations show benefit for patients with esophageal cancer who are often diagnosed after their disease has spread and would benefit from new therapeutic options.
Video
Megan May, PharmD, BCOP, Cecilia Lau, RPh, BCOP, APh, and Daneng Li, MD, share their thoughts on unmet needs in the management of neuroendocrine tumors.
April 08, 2021
A session at the Community Oncology Alliance virtual 2021 conference noted that clinical trials have found promising new treatments for patients with breast cancer, offering opportunities for future new approvals and indications.
In patients who received early palliative care, researchers noted a lower percentage of patients with depression, improved quality of life, and, significantly, longer survival.
Panelists at the Community Oncology Alliance (COA) virtual 2021 conference said the impacts of the pandemic on their day-to-day operations were challenging, although they all said they were proud of how their staff handled the rapid changes in spring of 2020.
Findings from the phase 3 ASCENT trial demonstrate a clinically meaningful 57% reduction in the risk of disease worsening or death for patients receiving sacituzumab govitecan.
Patients with glioblastoma receiving temozolomide in the morning had an average overall survival of about 17 months, compared to an average overall survival of approximately 13.5 months for those taking the drug in the evening.
Although many attendees and presenters are looking forward to returning to in-person conferences in the future, Anne Krolikowski said the virtual format of their upcoming conference allows even more people to attend.
